High-SSA Cannabinoid Crystal Powder for Sustained Oral Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral formulations of cannabinoids face challenges in achieving high and sustained uptake in the human body, often compromised by complex structures and formulations, particularly in optimizing total content and sustained effects in the bloodstream.
Innovation Solution
Cannabinoid crystal particles with a Specific Surface Area (SSA) of at least 0.7 m2/g, prepared through dry-milling, wet-milling, or re-crystallization, ensuring high purity and crystallinity, enhance uptake and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If complex formulations like SEDDS are used to achieve high uptake of cannabinoids, then the penetration of mucosal barriers is improved, but the device complexity and manufacturing cost increase
Solution Approach 1:
The patent extracts and isolates the critical property of high specific surface area from the complex SEDDS formulation, achieving high cannabinoid uptake through particle size optimization alone, without requiring surfactants, oils, or other complex SEDDS components
Solution Approach 2:
The invention replaces expensive and complex SEDDS formulations with simple, cost-effective cannabinoid powder consisting of high-specific surface area particles, eliminating the need for costly surfactants, oils, and multiple functional components
2Quantity of substance
If complex formulations like SEDDS are used to achieve high uptake of cannabinoids, then the penetration of mucosal barriers is improved, but the manufacturing cost increases
Solution Approach 1:
The patent employs inexpensive cannabinoid powder with optimized particle size, eliminating the need for costly SEDDS components such as surfactants, oils, and co-factors, thereby significantly reducing manufacturing costs while maintaining high cannabinoid uptake
3Device complexity
If conventional powder formulations are used, then the formulation simplicity is maintained, but the total content of cannabinoids delivered to the bloodstream is reduced
Solution Approach 1:
The invention changes the physical parameter of specific surface area by producing cannabinoid particles with SSA of at least 0.7 m2/g through controlled crystallization and milling processes, which dramatically increases the total cannabinoid content delivered to the bloodstream while keeping the formulation simple
4Device complexity
If conventional powder formulations are used, then the formulation simplicity is maintained, but the sustained delivery of cannabinoids is reduced
Solution Approach 1:
The patent optimizes the particle size and specific surface area parameters of cannabinoid crystals to achieve sustained delivery, where particles with SSA of at least 0.7 m2/g provide prolonged cannabinoid release over time while maintaining formulation simplicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The high SSA particles achieve a higher total content and sustained delivery of cannabinoids in the bloodstream, surpassing conventional powders, reducing the need for complex formulations like SEDDS.
Implementation Method 1
cannabinoid crystal particles having a relatively high Specific Surface Area (SSA)... achieve a higher total content and sustained delivery of cannabinoids in the bloodstream
Data Source
AI summary
A crystalline cannabinoid powder includes cannabinoid crystal particles having a cannabinoid purity of at least 95% by weight and a Specific Surface Area (SSA) of at least 0.7 m2/g. A crystalline cannabinoid powder includes cannabinoid crystal particles having a degree of crystallinity of at least 90% and a Specific Surface Area (SSA) of at least 0.7 m2/g. These powders may be prepared by a dry-milling or wet-milling method, and alternatively by a re-crystallization method.